The European Medicines Agency (EMA) on April 13, 2026, published data processing records for its EudraVigilance safety analytics platform, detailing how adverse drug reaction data are collected, stored, and analyzed to support pharmacovigilance across the European Union. The records, issued by EMA's Data Protection Office, outline the legal basis, purposes, and data subjects involved in the processing of personal data within the platform, impacting pharmaceutical companies, national competent authorities, healthcare professionals, and patients.
Document Context and Type
The publication is a formal record of processing activities required under Article 31 of Regulation (EU) 2018/1725, which governs personal data processing by EU institutions. It is a transparency measure, not a new policy or guideline, and does not introduce new obligations but clarifies existing data handling practices.
Policy Orientations and Trade-offs
The records emphasize the necessity of processing personal data—such as patient identifiers and healthcare professional details—to enable the detection of safety signals and the assessment of benefit-risk profiles of medicines. This approach balances public health protection against data privacy rights, with the agency asserting that processing is lawful under its public health mandate. The trade-off involves increased transparency for data subjects versus potential concerns over data minimization and retention periods.
Impact on Stakeholders
- Pharmaceutical companies: Must ensure their own data processing aligns with the documented practices, potentially requiring adjustments to their pharmacovigilance systems to comply with EMA's data protection standards.
- National competent authorities: Benefit from clearer understanding of data flows, facilitating cooperation in safety monitoring, but may face additional coordination requirements.
- Healthcare professionals and patients: Gain reassurance about how their data are used, though some may still have privacy concerns regarding the extent of data collection.
Expected Institutional Follow-up
The publication is part of EMA's ongoing commitment to data protection transparency. No immediate regulatory changes are expected, but the records may inform future audits or updates to the EudraVigilance system. The agency will continue to monitor compliance with data protection rules and may issue further guidance if needed.